Advertisement

Nailing the Right Dose! The Key for Developing Glycine Transporter Inhibitors for Schizophrenia

  • Daniel Umbricht
    Correspondence
    Address correspondence to Daniel Umbricht, M.D., Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. Building 1, Room 16.N655, Grenzacherstrasse 124, 4070 Basel, Switzerland.
    Affiliations
    Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Basel, Switzerland
    Search for articles by this author
      SEE CORRESPONDING ARTICLE ON PAGE 413
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • D’Souza D.C.
        • Carson R.E.
        • Driesen N.
        • Johannesen J.
        • Ranganathan M.
        • Krystal J.H.
        • and the Yale GlyT1 Study Group
        Dose-related target occupancy and effects on circuitry, behavior, and neuroplasticity of the glycine transporter-1 inhibitor PF-03463275 in healthy and schizophrenia subjects.
        Biol Psychiatry. 2018; 84: 413-421
        • Teyler T.J.
        • Hamm J.P.
        • Clapp W.C.
        • Johnson B.W.
        • Corballis M.C.
        • Kirk I.J.
        Long-term potentiation of human visual evoked responses.
        Eur J Neurosci. 2005; 21: 2045-2050
        • McNair N.A.
        • Clapp W.C.
        • Hamm J.P.
        • Teyler T.J.
        • Corballis M.C.
        • Kirk I.J.
        Spatial frequency-specific potentiation of human visual-evoked potentials.
        Neuroreport. 2006; 17: 739-741
        • Umbricht D.
        • Alberati D.
        • Martin-Facklam M.
        • Borroni E.
        • Youssef E.A.
        • Ostland M.
        • et al.
        Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: A randomized, double-blind, proof-of-concept study.
        JAMA Psychiatry. 2014; 71: 637-646
        • Dunayevich E.
        • Buchanan R.W.
        • Chen C.Y.
        • Yang J.
        • Nilsen J.
        • Dietrich J.M.
        • et al.
        Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia.
        Schizophr Res. 2017; 182: 90-97
        • Schoemaker J.H.
        • Jansen W.T.
        • Schipper J.
        • Szegedi A.
        The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: Results from the GIANT trial.
        J Clin Psychopharmacol. 2014; 34: 190-198
        • Martin-Facklam M.
        • Pizzagalli F.
        • Zhou Y.
        • Ostrowitzki S.
        • Raymont V.
        • Brasic J.R.
        • et al.
        Glycine transporter type 1 occupancy by bitopertin: A positron emission tomography study in healthy volunteers.
        Neuropsychopharmacology. 2013; 38: 504-512
        • Martina M.
        • Gorfinkel Y.
        • Halman S.
        • Lowe J.A.
        • Periyalwar P.
        • Schmidt C.J.
        • et al.
        Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels.
        J Physiol. 2004; 557: 489-500
        • Nong Y.
        • Huang Y.Q.
        • Ju W.
        • Kalia L.V.
        • Ahmadian G.
        • Wang Y.T.
        • et al.
        Glycine binding primes NMDA receptor internalization.
        Nature. 2003; 422: 302-307
        • Fraguas D.
        • Diaz-Caneja C.M.
        • Pina-Camacho L.
        • Umbricht D.
        • Arango C.
        Predictors of placebo response in pharmacological clinical trials of negative symptoms in schizophrenia: A meta-regression analysis.
        Schizophr Bull. 2018; ([published online ahead of print Jan 19])

      Linked Article